Vaxart's financial profile is defined by extreme revenue volatility, as evidenced by the sharp decline from $104.2 million in 2025Q4 to $39.2 million in 2026Q1, driven by a reliance on non-recurring government grants rather than commercial product sales. While...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.06+50.0% vs -$0.12 | $27M+3.7% vs $26M |
Q2 2026 May 7, 2026 | $0.02+0.0% vs $0.02 | $39M-40.1% vs $66M |
Q2 2026 Mar 12, 2026 | -$0.11-120.0% vs -$0.05 | $104M+49.6% vs $70M |
Q4 2025 Nov 13, 2025 | -$0.04+42.9% vs -$0.07 | $72M+101.4% vs $36M |
Vaxart OTCMKTS: VXRT Chief Executive Officer Steve Lo outlined the company's oral vaccine platform, its government-funded COVID-19 study and development opportunities in norovirus and influenza during an H.C. Wainwright conference presentation.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that a member of its management team will present at the H.C.
European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European markets European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European markets
Vaxart OTCMKTS: VXRT said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data from the larger, approximately 5,000-participant main cohort in the first half of 2027.
Benchmark VXRT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vaxart, Inc. (VXRT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.47 | $113.74M | 6.71 | 726.68% | 6.88% | 22.26% | — | |
| $10.55 | $1.73B | 4.15 | 64.69% | -59.87% | — | — | |
| $8.63 | $9.04B | -22.71 | 668.31% | -598.56% | — | — | |
| $1.10 | $1.23M | -0.03 | -84.1% | -6523.04% | -210.99% | — | |
| $1.00 | $339.11M | -4.35 | 8.83% | -1786.27% | — | — | |
| $0.41 | $15.12M | -1.80 | -64.74% | -219.5% | -2918.1% | — |
Vaxart, Inc. (VXRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vaxart, Inc. (VXRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 28, 2026·SEC
Jul 17, 2026·SEC
Mar 13, 2026·SEC
Get notified when VXRT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vaxart, Inc. (VXRT) stock FAQ — growth, dividends, profitability & financials explained
Vaxart, Inc. (VXRT) reported $243.1M in revenue for fiscal year 2025. This represents a 1% increase from $239.9M in 1996.
Vaxart, Inc. (VXRT) grew revenue by 726.7% over the past year. This is strong growth.
Yes, Vaxart, Inc. (VXRT) is profitable, generating $38.6M in net income for fiscal year 2025 (6.9% net margin).
Vaxart, Inc. (VXRT) has a return on equity (ROE) of 22.3%. This is excellent, indicating efficient use of shareholder capital.
Vaxart, Inc. (VXRT) generated $33.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
